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Passive tension over the entire range of sarcomere lengths did not differ be-
tween sarcomere-mutation positive and mutation-negative male HCM patients.
Passive tension in myocytes from sarcomere mutation-positive women was
significantly higher compared to female mutation-negative HCM patients. Fe-
male MYH7 cardiomyocytes showed a higher sarcomere stiffness compared to
male MYH7.
Conclusion
Our measurements suggest that high sarcomere passive stiffness may
contribute to diastolic dysfunction in female HCM patients harboring a muta-
tion in genes encoding thick filament proteins.
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Mammalian hearts express two myosin heavy chain (MHC) isoforms, which
drive contractions with different kinetics and power-generating ability. The
expression of the isoform that is associated with more rapid contraction kinetics
and greater power output, MHC-a, is down-regulated, with a concurrent in-
crease in the relative amount of the slower isoform, MHC-b, during the pro-
gression to experimentally-induced or disease-related heart failure. This
change in protein expression has been well studied in right and left ventricles
in heart failure models and in humans with failure. Relatively little quantitative
data exists regarding MHC isoform expression shifts in human failing atria. We
previously reported significant increases in the relative amount of MHC-b in
the human failing left atrium. The results of that study suggested that there
might be a sex-related difference in the level of MHC-b in the left atrium,
but the number of female subjects was insufficient for statistical analysis.
The objective of this study was to test whether there is, in fact, a sex-related
difference in the level of MHC-b in the right and left atria of humans with car-
diomyopathy. The results indicate that significant differences exist in atrial
MHC isoform expression between men and women who are in failure. The re-
sults unexpectedly also revealed a two-fold greater amount of MHC-b in the
non-failing left atrium of women, compared to men. The observed sex-
related differences in MHC isoform expression could impact ventricular dia-
stolic filling during normal daily activities, as well as during physiologically
stressful events.
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Rationale: Myocardial infarction (MI) is associated with depressed cardiac con-
tractile function and progression to heart failure. Cardiac myosin binding
protein-C (cMyBP-C), a cardiac-specific myofilament protein, is proteolyzed
post-MI in humans and results in an N-terminal fragment, C0C1f. The presence
of C0C1f in cultured adult cardiomyocytes results in decreased Ca2þ transients
and cell shortening, in addition to the induction of heart failure in a mouse
model. However, the underlying mechanisms remain unclear.
Objective: To determine how C0C1f causes altered contractility in human car-
diac myofilaments in vitro.
Methods and Results: We generated recombinant human C0C1f (hC0C1f) and
incorporated it into skinned human left ventricular myocytes. Mechanical prop-
erties were then studied at sarcomere lengths of 2.0 and 2.3 mm. Our data
demonstrate that the presence of hC0C1f in the sarcomere decreased maximal
force myofilament Ca2þ sensitivity, increased cooperative activation at short
lengths and enhanced length-dependent activation. Furthermore, hC0C1f led
to increased cross-bridge cycling kinetics and tension cost at both short and
long sarcomere lengths. We further established that the detrimental effects of
hC0C1f occur through direct interaction with the thin filament proteins actin
and a-tropomyosin (a-TM).Conclusions: Our data demonstrate that the presence of hC0C1f in the sarco-
mere is sufficient to induce depressed myofilament function and Ca2þ sensi-
tivity in otherwise healthy human donor myofilament preparations.
Decreased cardiac function post-MI may result, in part, from the ability of
hC0C1f to bind actin and a-TM, suggesting that cleaved C0C1f could act as
a poison peptide and disrupt the interaction of native cMyBP-C with the thin
filament.
Keywords: Cross-bridge cycling kinetics; length-dependent activation;
cMyBP-C; C0C1f protein.
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Background: Rest or exercise obstruction is present in two thirds of patients
with hypertrophic cardiomyopathy (HCM) and is a major determinant of symp-
toms and disability. Hypercontractile upper septum is the main pathophysiolog-
ical determinant of obstruction, thus negative inotropic interventions such as
dysopiramide or beta-blockers are the only available options to pharmacolog-
ically treat obstruction, commonly with partial efficacy. We have previously
demonstrated that ranolazine ameliorates diastolic function in trabeculae
from septal samples of obstructive HCM patients undergoing myectomy (Cop-
pini et al, Circulation 2013).
Methods: Patch clamp studies and intracellular Ca2þ recordings were per-
formed in isolated myocytes from myectomy samples of obstructive HCM pa-
tients; intact trabeculae were used for mechanical measurements. Myocardial
specimens from non-failing non-hypertrophic patients or patients with second-
ary hypertrophy were used as controls.
Results: Dysopiramide (Dys) reduced twitch tension in a dose dependent
manner and 5mM Dys accelerated contraction kinetics in HCM trabeculae.
Isoproterenol 107 mol/L (Iso) determined a significant potentiation of twitch
amplitude and an accelleration of contraction kinetics (both time to peak and
relaxation). Changes induced by Iso in control trabeculae were similar. Inter-
estingly, Iso caused APD prolongation in HCM cardiomyocytes instead of
the shortening observed in control cells. This was likely related to the unbal-
ance between depolarizing and repolarizing currents, including increased
Late-Naþ current (INaL). The INaL blocker Ranolazine 10 mM (Ran) applied
on top of Iso (IsoþRan) markedly reduced isometric twitch tension of
HCM trabeculae, while Ran alone showed no negative inotropic effect.
Contraction kinetics in IsoþRan were still significantly faster compared to
baseline.
Conclusions: Beta adrenergic stimulation may enhance septal contractility
and determine obstruction in HCM. Ranolazine, by reducing septal tension at
peak exercise but not at rest, may represent a safe therapeutic option for
obstruction.
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We examined the role of missense and nonsense myosin-binding protein
mutations in human tissue of patients with hypertrophic cardiomyopathy
in an essentially unloaded isotonic system by partial Ca2þ-activation, i.e.
Ca-spontaneous oscillary contractions (SPOC). Despite considerable litera-
ture suggesting that hypercontractility is a feature of HCM-causing muta-
tions, we observe: (1) prolonged durations of both the lengthening
(p<0.0001) and shortening (p<0.001) phases of the SPOC cycle in
MYBPC3 mutants; (2) depressed contractility where the rates of both
lengthening (P<0.01) and shortening (p<0.05) were reduced; however (3)
the amplitude of the SPOC cycles did not vary between mutated MYBPC3
and healthy donor samples under essentially unloaded isotonic conditions.
We found no difference between MYBPC3 samples containing missense
or nonsense mutations. Unexpectedly, principal component analysis demon-
strated that the contractile properties of human derived cardiomyocytes un-
der low-load conditions were distinctively different for mutations in
MYBPC3 and troponin genes. We conclude that, at least under the isotonic
348a Monday, February 17, 2014Ca-activated SPOC conditions: (1) MYBPC3 mutants display depressed
contractility; (2) this effect is independent of the gene variant but is consis-
tent with a mechanism of haplotype insufficiency (rather than ‘‘poison pep-
tide’’ effect); and (3) HCM mutations display different phenotypes when
examined under conditions of low strain.
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While a number of factors underlie cardiac dysfunction in HF, recent atten-
tion has fallen on phosphorylation changes in myofilament proteins, notably
the regulatory proteins. Cardiac myosin regulatory light chain (cMLC2) is a
166 amino acid protein located on the hinge region of myosin heavy chain
and optimally positioned to modulate contraction. Recent studies have shown
that cMLC2v contributes to regulating cardiac pump function and allows for
beat-to-beat tuning of the myosin motor arm. Humans, as well as large ro-
dents such as rabbits, have high sequence homology and a single phosphor-
ylation site at ser15. We hypothesize that human MLC2v phosphorylation is
a critical regulator of myocyte contraction that is dysregulated in HF and
that increasing MLC2v phosphorylation with myosin light chain kinase
(MLCK) can partially reverse the dysfunction seen with HF. Human donor
or HF permeabilized cardiac tissue were incubated with either alkaline phos-
phatase to reduce phosphorylation or PKA to induce maximal phosphoryla-
tion of the other myofilament proteins. Maximal cMLC2v phosphorylation
was then achieved by incubation with MLCK. Force-calcium relationship,
rate of tension redevelopment, tension cost and length dependent activation
was determined. To assess the role of cMLC2v phosphorylation on dynamic
regulation of length dependent activation, intact rabbit cardiomyocytes were
isolated from rabbit hearts and transfected with MLCK to provide maximal
cMLC2v phosphorylation. Cells were then attached using a force transducer
and length controller and a simulated length-force relationship, which
approximate the pressure-volume relationship in vivo, was evaluated at
different diastolic sarcomere lengths. We show that MLC2v phosphorylation
is a critical regulator of myocyte contraction that is dysregulated in the
failing heart and treatment with MLCK can partially reverse the dysfunction
seen with HF.
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Heart failure affects more than 5 million patients in the United States. The
mechanisms by which the heart regulates cross-bridge cycling rate and if
and how such regulation is altered in heart failure are poorly understood.
One possible modulator of this cycling rate is muscle length. In a previously
published study, we showed that the rate of tension redevelopment (ktr) can be
reproducibly measured in intact cardiac trabeculae using a novel approach.
Furthermore, we showed that slacking trabeculae from Lopt corresponding
to end-diastolic volume in vivo) to L90 (corresponding to end-systolic volume
in vivo) increases ktr by about 60%. While this regulation is present in a small
animal model, its role in human myocardium in both health and disease re-
mains unanswered. Therefore, we extended our studies using our novel
method to right ventricular trabeculae isolated from non-failing donor and pa-
tients with heart failure. The failing samples had preserved length-tension
relationship, reduced force-frequency relationship, and b-adrenergic desensiti-
zation as compared to non-failing donors. Contractile and relaxation kinetics
of twitch of both non-failing and failing trabeculae were slowed down with
increasing muscle length from L90 to Lopt. We were able to reproducibly mea-
sure ktr in intact human cardiac trabeculae; ktr during maximal myofilament
activation in both non-failing and failing samples decreased with increasing
muscle length. This effect of muscle length on ktr was also present at sub-
maximal activation. These effects can be potentially due to post-
translational modifications. We have preliminary ktr data after rapid length
changes during maximal activation and PKA/PKCBII inhibition at maximal
and sub-maximal activation levels. The overall data provides evidence that
muscle length can regulate cross-bridge cycling kinetics in both non-failing
and failing human hearts.1757-Pos Board B487
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Background and Rationale: we have previously shown that the myocardium
of patients with Hypertrophic Cardiomyopathy (HCM) shows increased CaM-
KII activity with respect to non-HCM non-failing surgical patients (controls).
We found higher phosphorylation levels of several tested CaMKII targets,
such as L-Type Ca2þ channels, Naþ channels and phospholamban (Coppini
et al., Circulation 2013). Such changes are likely to determine significant dele-
terious effects on the electrical and mechanical function of HCM
myocardium.
Methods: we assessed the effects of a selective inhibitor of CaMKII, the cell-
permeant Autocamtide-related Inhibitory Peptide II (AIP-II), on force and
intracellular Ca2þ in intact trabeculae and cardiomyocytes isolated from surgi-
cal septal samples of HCM patients who underwent myectomy.
Results: HCM trabeculae display an increased diastolic tension and a slower
kinetics of isometric force generation when compared to control trabeculae.
AIP-II determines a reduction of diastolic tension, with larger effects at fast
pacing rates (1353 % at 2Hz). Additionally, AIP-II accelerated the kinetics
of force generation in HCM muscles (time to peak contraction at 1Hz:
255517 ms at baseline vs. 232510 ms with AIP-II, p<0.05). Accordingly,
in HCM cardiomyocytes AIP-II lowered intracellular diastolic Ca2þ levels
(from 278 5 40 nM to 159 5 28 nM, p<0.01) and reduced the frequency-
dependent increase of diastolic [Ca2þ]. The kinetics of Ca2þ transients, how-
ever, were not significantly affected by AIP-II. This suggests that reduced
CaMKII phosphorylation of myofilament proteins may underlie the acceler-
ated contractile kinetics observed in HCM trabeculae following AIP-II
exposure.
Discussion: The results indicate that increased activation of CaMKII plays a
significant role in determining the abnormalities of myocardial contraction in
HCM. Pharmacological inhibition of CaMKII may represent a viable option
to reduce diastolic dysfunction in HCM patients.
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Mutations in cardiac troponin T (cTnT) have been linked to hypertrophic car-
diomyopathy (HCM). Previous experiments in our lab utilizing a novel cTnT
R92L transgenic mouse model revealed an allosterically mediated decrease in
the PKA phosphorylation potential of cardiac troponin I (cTnI). We hypoth-
esized the cTnT R92L mutation causes a change in the dynamics of the N-
terminal extension, hindering the availability of PKA substrates S23/S24 on
cTnI. In the current study this hypothesis was tested both in silico and
in vitro. First, molecular dynamics (MD) simulations using our all-atom
thin filament model in the Ca2þ saturated state were performed. MD pre-
dicted an approximately 7A˚ narrowing between the N-terminal extension
of cTnI and cardiac troponin C (cTnC). To experimentally evaluate the in-
silico predictions, Fo¨rster Resonance Energy Transfer (FRET) experiments
were conducted on fully reconstituted thin filaments. The cTnI was labeled
with the FRET donor AEDANS at three sites on the N-terminal extension
of cTnI. The acceptor DDPM, was labeled on six sites on cTnC. Steady state
and time resolved FRET experiments were performed in the presence and
absence of the TnT R92L mutation. Both theoretical and experimental ap-
proaches revealed that in the presence of the cTnT R92L mutation the dy-
namics of cTnI was allosterically altered. The N-terminal extension of
cardiac troponin I moved closer to the N-domain of cTnC. This anharmonic
fluctuation likely hinders the availability of the PKA substrate sites and leads
to the observed blunting of the beta-adrenergic response in animal models
and human patients.
